Zurcher Kantonalbank Zurich Cantonalbank Has $1.56 Million Position in Catalent, Inc. (NYSE:CTLT)

Zurcher Kantonalbank Zurich Cantonalbank lessened its position in Catalent, Inc. (NYSE:CTLT) by 58.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 34,681 shares of the company’s stock after selling 48,781 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Catalent were worth $1,558,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of CTLT. CWM LLC raised its position in Catalent by 19.7% in the 3rd quarter. CWM LLC now owns 6,113 shares of the company’s stock valued at $278,000 after buying an additional 1,005 shares during the last quarter. Exchange Traded Concepts LLC bought a new position in Catalent in the third quarter valued at approximately $31,000. Czech National Bank grew its stake in Catalent by 47.8% in the third quarter. Czech National Bank now owns 31,508 shares of the company’s stock valued at $1,435,000 after purchasing an additional 10,189 shares in the last quarter. Asset Management One Co. Ltd. grew its stake in Catalent by 9.3% in the third quarter. Asset Management One Co. Ltd. now owns 76,471 shares of the company’s stock valued at $3,482,000 after purchasing an additional 6,490 shares in the last quarter. Finally, Simplicity Solutions LLC bought a new position in Catalent in the third quarter valued at approximately $1,603,000.

Analyst Ratings Changes

CTLT has been the subject of a number of analyst reports. Stephens restated an “equal weight” rating and issued a $63.50 price target on shares of Catalent in a research note on Thursday, April 4th. Barclays raised their price target on Catalent from $45.00 to $47.00 and gave the company an “equal weight” rating in a research note on Thursday, January 25th. Royal Bank of Canada restated a “sector perform” rating and issued a $63.50 price target on shares of Catalent in a research note on Tuesday, February 20th. UBS Group restated a “neutral” rating and issued a $63.50 price target (up from $58.00) on shares of Catalent in a research note on Tuesday, February 6th. Finally, StockNews.com initiated coverage on Catalent in a research note on Friday, April 19th. They set a “sell” rating for the company. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and three have issued a buy rating to the company. According to MarketBeat, Catalent presently has a consensus rating of “Hold” and an average price target of $52.46.

Catalent Stock Performance

CTLT opened at $55.81 on Friday. The business has a fifty day simple moving average of $56.76 and a 200 day simple moving average of $48.53. The company has a market capitalization of $10.10 billion, a PE ratio of -8.21, a price-to-earnings-growth ratio of 6.04 and a beta of 1.20. Catalent, Inc. has a 1 year low of $31.45 and a 1 year high of $60.20. The company has a debt-to-equity ratio of 1.34, a current ratio of 2.48 and a quick ratio of 1.73.

Catalent (NYSE:CTLT) last released its quarterly earnings results on Friday, February 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.22). The firm had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.01 billion. Catalent had a negative net margin of 29.91% and a negative return on equity of 2.43%. The business’s revenue for the quarter was down 10.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.62 earnings per share. Research analysts expect that Catalent, Inc. will post 0.28 EPS for the current year.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.